OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Rheumatology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Composite endpoints for Sjögren's Syndrome	529
Is it Autumn for colchicine and osteoarthritis?	470
Cardiovascular risk in gout: time for action	274
Thank you to The Lancet Rheumatology's peer reviewers in 2023	229
FDA approval for anifrolumab in patients with lupus	184
Pausing drugs and spacing vaccines: an open question	173
The inclusion of Indigenous voices in health research	156
Rheumatic cognitive impairment: a new clinical entity?	142
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	133
Immunoglobulin, glucocorticoid, or combined therapy for multisystem inflammatory syndrome in children	132
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	127
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	126
Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study	109
Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational s	107
The projected burden of arthritis among adults and children in Australia to the year 2040: a population-level forecasting study	107
Tumour necrosis factor inhibitor safety in rheumatoid arthritis-associated interstitial lung disease	104
Performance of large language models in rheumatology board-like questions: accuracy, quality, and safety	103
Integrating evidence from lived experience of Aboriginal people and clinical practice guidelines to develop arthritis educational resources: a mixed-methods study	88
Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospita	86
Research in Brief	82
Toxic epidermal necrosis-like acute cutaneous lupus erythematosus	78
Novel COVID-19 therapies: the road ahead for rheumatology	76
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry	74
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort stud	72
Brett Thombs: an unconventional journey	70

Research in Brief	69
Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know	68
Survivorship of revised and multiply revised knee replacements	59
Research in Brief	57
Research in Brief	55
Research in Brief	54
The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution	54
Reigniting the burnt-out health-care workforce	53
Cervical spinal gout	49
Correction to Lancet Rheumatol 2020; 2: e557–64	49
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	49
Research in Brief	48
Long-awaited action on rare diseases	47
Pandemic to endemic: optimising COVID-19 immunity	46
Can contextual factors improve clarity of the results from clinical trials of low back pain?	45
The influence of safety warnings on the prescribing of JAK inhibitors	44
Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs	44
Patient–researcher co-presentation of research results to people living with systemic sclerosis	44
Titilola (Lola) Falasinnu: looking out for the overlooked	43
Research in Brief	43
Towards improving the Global Burden of Disease estimates for low back pain	43
Differential effects of oestrogen on class-switch recombination of B cells dependent on sex chromosome complement: a cross-sectional study	42
Optimal non-opioid analgesic combinations after total hip arthroplasty	41
The outcomes of children born to mothers with autoimmune rheumatic diseases	41
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	40
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	40
Research in Brief	39
Severe COVID-19 as a virus-independent immunothrombotic process – Authors' reply	39
Thank you to The Lancet Rheumatology's peer reviewers in 2022	39
Severe COVID-19 as a virus-independent immunothrombotic process	39
Research in Brief	38
Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind,	38
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	37
Whole-body MRI for juvenile idiopathic arthritis	37
Exploring gender differences, medical history, and treatments used in patients with fibromyalgia in the UK using primary-care data: a retrospective, population-based, cohort study	35
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	35
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study	34
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab	34
National differences in vaccine hesitancy: a concern for the external validity of vaccine studies	34
Biological disease-modification in axial spondyloarthritis: insights from MRI	34
Industry involvement in rheumatology consensus-based recommendations: a systematic review	33
Patient and public involvement in rheumatology research: embracing the wave of change	33
The role of antirheumatics in patients with COVID-19	33
How should we define disease and outcomes in axial psoriatic arthritis?	33
Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study	32
Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial	32
Palliative care in patients with rheumatic diseases	32
Research, pregnancy, and the ethics of parental consent	32
Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework	32
Dermatology response to the Hyperinflammation and HLH Across Specialty Collaboration consensus guideline – Authors' reply	31

Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inflammatory multisystem syndrome temporally associated with COVID-19	31
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	30
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	30
TNF inhibitor use during pregnancy in axial spondyloarthritis: are we asking the right questions?	30
COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey	29
Patient-led research in rheumatology: the way forward?	29
Research in Brief	29
Vasculitis: the promising road ahead	28
Structural racism is a driver of fragmented care and acute care use among people with rheumatic conditions	27
Susac syndrome: challenges of interpreting treatment data in a rare disease	27
Flare of rheumatoid arthritis after COVID-19 vaccination	26
Research in Brief	26
Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study	25
Getting serious about sex and gender	25
Research in Brief	24
Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve	23
Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus	23
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study	23
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	23
Uveitis relapse in Behçet's disease: a more nuanced approach is needed	22
Correction to Lancet Rheumatol 2023; 5: e274–83	22
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial	22
FDA expands JAK inhibitors warning: going beyond the data?	22
Correction to Lancet Rheumatol 2022; 4: e853–63	22
Clinical assessment and management of lumbar spinal stenosis: clinical dilemmas and considerations for surgical referral	22
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longit	22
Challenges of a stratified care approach to musculoskeletal pain	22
Correction to Lancet Rheumatol 2022; 4: e177–87	21
Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, fea	21
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial	21
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies	21
A disseminated gonococcal infection with spinal locations	21
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	21
Burden of rheumatoid arthritis and forecasted prevalence to 2050	20
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial	20
The effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective coho	19
Precision medicine in Sjögren's disease	19
Time to talk to adults with rheumatic diseases about herpes zoster vaccination	18
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	18
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	18
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a	18
Understanding the multiple dimensions of ageing: 5Ms for the rheumatologist	18
Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort	17
Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline	17
Allogeneic haematopoietic stem-cell transplantation in systemic juvenile idiopathic arthritis	17
Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial	17
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study	17
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	16
Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study	16
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	16
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-con	16
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure	16
Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	16
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	16
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	16
The influence of sex hormones on musculoskeletal pain and osteoarthritis	15
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study	15
Gout prevalence is rising in low-income and middle-income countries: are we ready?	15
Gender distribution of rheumatologists across Africa (REACT): a cross-sectional survey study	15
The same genotype gives rise to a spectrum of disorders	15
Calcium pyrophosphate deposition disease	15
Women in rheumatology in Africa	15
Idiopathic inflammatory myopathies: current insights and future frontiers	15
Navigating the complexities of pregnancy in rheumatic disease	14
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinat	14
Improving polymyalgia rheumatica care: considerations for routine vascular ultrasound in clinical practice	14
Treating subclinical arthritis: prevention or overtreatment?	14
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Ear	14
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study	14
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases	14
Research in Brief	14
Is type I interferon score a promising circulating biomarker for systemic sclerosis?	14
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	14
Trends in opioid use for autoimmune rheumatic diseases	14
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis	13
Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease	13
Rhombencephalitis with longitudinal extensive transverse myelitis in lupus: an overlap syndrome?	13
Patients with gout: an under-recognised group at high risk of COVID-19	13
Game-changing therapies for people with giant cell arteritis?	13
Central sensitisation: causes, therapies, and terminology – Authors' reply	13

Composite endpoints for Sjögren's Syndrome	13
Preventive medicine in rheumatology: COVID-19 and its lessons for better health outcomes	12
Risks and benefits of tocilizumab monotherapy in giant cell arteritis	12
Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination	12
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study	12
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study	12
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	12
Expanding role of biomarkers in characterising hyperinflammatory syndromes – Authors' reply	12
Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage	12
No perfect therapy for the imperfect COVID-19 cytokine storm	12
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort	12
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	12
Tapering of disease-modifying antirheumatic drugs: an overview for daily practice	12
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	11
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	11
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study	11
Celebrating progress in the vasculitides, old and new	11
Association of economic insecurities with patient-reported outcomes in systemic lupus erythematosus	11
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	11
Allogeneic mesenchymal stromal cell transplantation for systemic sclerosis	11
Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences	11
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicent	11
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, contro	11
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	10
Review or perish, regardless of your attempts to publish	10
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	10
Tuning up UK clinical trials	10
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study	10
Systemic lupus erythematosus: managing cardiovascular risk factors	10
Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient care	10
Pausing drugs and spacing vaccines: an open question – Authors' reply	10
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	10
Non-opioid analgesic combinations following total hip arthroplasty (RECIPE): a randomised, placebo-controlled, blinded, multicentre trial	10
Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study	10
Correction to Lancet Rheumatol 2020; 2: e666–76	10
Michael Barrett: navigating hostile terrain	10
JAK inhibitors—Friend or Foe?	9
COVID-19 vaccination advice via SMS-based video to improve vaccination uncertainty in at-risk groups	9
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	9
Research in Brief	9
Assessment of treatment efficacy in polymyalgia rheumatica	9
Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine	9
Welcome new evidence on self-management of back pain	9
Stop ticking boxes: it just doesn't work	9
Thank you to our contributors and peer reviewers in 2023	9
Progressive unilateral facial asymmetry in a young girl	9
Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies	9
Sex bias in IgG4-related disease: from clinical phenotype to mechanisms	9
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	9
Research in Brief	8
Adolescent sarcoidosis mimicking malignant lymphoma	8
Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people	8
Early-stage Dupuytren's disease treatment; a promising next step?	8
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study	8
Pain in the joints and beyond; the challenge of rheumatoid arthritis	8
Large language models and rheumatology: a comparative evaluation	8
Role of plasma exchange in ANCA-associated vasculitis	8
Therapeutic implications of ongoing alveolar viral replication in COVID-19	8
Getting better at quantifying the toxicity of glucocorticoids	7
Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders	7
Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study	7
Targeting mTOR in sarcoid granulomas: where the rubber meets the road	7
Predicting COVID-19 vaccination response in populations who are immunosuppressed	7
Therapeutic drug monitoring countering the effect of anti-infliximab antibodies	7
Assessing glucocorticoid toxicity: are the measures sensitive enough?	7
Painful scalp nodules in SAPHO syndrome	7
Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis	7
Potential for false decline of anti-SARS-CoV-2 spike antibody titers after COVID-19 vaccination	6
Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled	6
Riociguat in systemic sclerosis: challenges in crossing the bridge from bench to bedside	6
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	6
Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease – Authors' reply	6
Correction to Lancet Rheumatol 2022; 4: e163–66	6
The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology	6
Leflunomide in the treatment of psoriatic arthritis	6
New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?	6
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply	6
Gender differences in the incidence of systemic lupus erythematosus in Norway: a population-based cohort study	6
A molecular signature as a guidance for glucocorticoid: are we there yet?	5
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial	5
Research in Brief	5
A new tool for stratifying children with suspected Sjögren's disease	5
Adult-onset Still's disease after mRNA COVID-19 vaccine	5
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	5
Protecting patients with SLE against herpes zoster: time for early proactive vaccine counselling	5
Latika Gupta: a thinker and a doer for myositis research	5
Increased risk of severe COVID-19 outcomes in patients with rheumatoid arthritis and interstitial lung disease	5
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	5
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	5
COVID-19 vaccine data provide reassurance	5
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies	5
Bilateral linear scleroderma with transition into progressive facial hemiatrophy	5
2022: a banner year for systemic lupus erythematosus?	5
Investigating sex differences in T regulatory cells from cisgender and transgender healthy individuals and patients with autoimmune inflammatory disease: a cross-sectional study	5
Research in Brief	5